Delivery Order SPE2DR25D3003-SPE2DR26F5QE8
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,107.42 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on December 2, 2025, with an ultimate completion date of December 3, 2025. This non-set-aside, competitively awarded contract employs firm fixed price terms and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $7,509.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on August 19, 2025, with ultimate completion scheduled for August 20, 2025. This competitive award, placed under no set-aside designation, represents a child delivery order issued against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement...
- The Defense Logistics Agency awarded a $1,960.14 delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on September 24, 2025, with completion scheduled for September 25, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The order will be fulfilled from the vendor's...
- The Defense Logistics Agency awarded a $4,080.45 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on September 19, 2025, with completion scheduled for September 22, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $6,644.52 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on December 3, 2025, with completion targeted for December 4, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of Zepbound 7.5 mg/0.5 mL pen injections valued at $10,966.72. The order was awarded on November 3, 2025, on a firm fixed-price basis with an ultimate completion date of November 4, 2025, with no set-aside designation applied. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $11,268.06 to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. This firm fixed-price delivery order, with an ultimate completion date of September 23, 2025, represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award was...
- The Defense Logistics Agency awarded a $14,455.29 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injections. This firm fixed-price contract, with an ultimate completion date of August 5, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injections with a ceiling value of $5,141.16. This is a firm fixed-price delivery order with no set-aside designation, issued under a competitive procurement process. The order is set for completion by September 11, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania facility. This delivery order is a child contract issued...
- The Defense Logistics Agency awarded a $42,081.30 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections with a completion date of September 16, 2025. This is a non-set-aside competitive award issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The work will be...
- SPE2DR25D3003Indefinite Delivery Contract
- SPE2DR25D3003-SPE2DR26F5QE8Delivery Order
The Defense Logistics Agency awarded a delivery order valued at approximately $35.9K to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on December 4, 2025, with completion scheduled for December 5, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement supporting military and veteran healthcare systems. The company's prime indefinite delivery vehicle with DLA enables the supply of a comprehensive range of pharmaceutical products and medical supplies across multiple therapeutic domains to support Defense Health Agency operations and other government healthcare systems globally. This specific delivery order for Zepbound, a GLP-1 receptor agonist used in diabetes and weight management treatment, reflects the company's role in supplying both specialty medications and brand-name pharmaceuticals to federal customers through the DLA Medical Supply Chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $35.9k | 12/3/25 |